U.S. Water Utilities Stock News

NasdaqGS:VNET
NasdaqGS:VNETIT

VNET Group (VNET) Is Up 7.8% After Discounted Equity Sale And CFO Exit News – Has The Bull Case Changed?

VNET Group recently announced a US$137.7 million follow-on equity offering at a steep discount and confirmed the past resignation of CFO Qiyu Wang, moves that have raised concerns about shareholder dilution and leadership continuity. The company was also removed from a major investment bank's Asia-Pacific Conviction List, highlighting wavering institutional confidence at a time when its financing choices are under scrutiny. Against this backdrop of discounted equity issuance, we'll now...
NYSE:RYZ
NYSE:RYZMetals and Mining

Will Ryerson's (RYZ) Q1 Profit Return and ESOP Shelf Offering Recast Its Equity Strategy Narrative?

Ryerson Holding Corporation recently reported past first-quarter 2026 results, with sales rising to US$1,566.5 million and net income reaching US$4.5 million, alongside a return to positive earnings per share from continuing operations. On the same day, the company also filed a US$50.22 million shelf registration for 1,800,000 common shares tied to an ESOP-related offering, underscoring its use of equity for employee benefit plans. We will now examine how Ryerson’s return to profitability...
NasdaqGS:TSHA
NasdaqGS:TSHABiotechs

A Look At Taysha Gene Therapies (TSHA) Valuation After FDA Alignment On TSHA-102 BLA Pathway

Taysha Gene Therapies (TSHA) has reaffirmed FDA alignment on the Biologics License Application pathway for TSHA-102, including pivotal trial design and the potential use of a six month interim analysis for approval. See our latest analysis for Taysha Gene Therapies. The reaffirmed FDA pathway comes after a run in the stock, with a 30 day share price return of 45.95% and a 1 year total shareholder return of 217.62%. This signals strong momentum despite recent earnings losses and ongoing cash...
NasdaqGS:LLYV.K
NasdaqGS:LLYV.KConsumer Services

Liberty Live’s Rising Revenue and Deeper Losses Could Be A Game Changer For Liberty Live Holdings (LLYV.K)

Liberty Live Holdings, Inc. reported first-quarter 2026 results, with revenue rising to US$63.62 million from US$47.06 million a year earlier, while net loss widened to US$294.14 million from US$29.48 million. This combination of higher sales and a much larger loss highlights how Liberty Live Holdings is balancing growth with the cost of its operations. Next, we’ll examine how the sharp increase in net loss alongside revenue growth shapes Liberty Live Holdings’ broader investment...
NYSE:BKE
NYSE:BKESpecialty Retail

Do Buckle’s Steady Comps Signal Durable Brand Strength or Just Near-Term Resilience for BKE?

The Buckle, Inc. recently reported that for the 4-week period ended May 2, 2026, comparable store net sales edged up 0.2% and total net sales rose to US$86.3 million, while year-to-date 13-week net sales increased to US$288.7 million. An interesting takeaway is that Buckle’s modest monthly comparable growth contrasts with a stronger 5.1% year-to-date comparable sales increase, highlighting resilience across the broader quarter. We’ll now examine how this solid 5.1% year-to-date comparable...
NYSE:HUN
NYSE:HUNChemicals

Did Huntsman’s Wider Q1 Loss and Governance Vote Just Shift Huntsman's (HUN) Investment Narrative?

Huntsman Corporation recently reported first-quarter 2026 results showing sales of US$1,420 million and a net loss of US$53 million, while shareholders voted against a proposal for an independent board chair and the company affirmed a quarterly dividend of US$0.0875 per share. These developments, alongside ongoing restructuring and European plant-closure programs discussed in earlier filings, highlight the cost and governance pressures shaping Huntsman’s current operating profile. We’ll now...
NasdaqGS:TOWN
NasdaqGS:TOWNBanks

TowneBank (TOWN) Valuation Check As Recent Trading Leaves Mixed Short And Long Term Returns

TowneBank (TOWN) stock drew attention after recent trading left it modestly higher over the past week, but lower over the past month and over the past three months, prompting closer inspection of its fundamentals. See our latest analysis for TowneBank. At a share price of $34.99, TowneBank has a 1-day share price return of 0.46% and a year to date share price return of 5.33%, while its 3 year total shareholder return of 80.75% points to stronger momentum over the longer term. If TowneBank’s...
NasdaqGS:AGNC
NasdaqGS:AGNCMortgage REITs

Is AGNC Investment (AGNC) Still Attractive After Strong One Year Share Price Gain?

If you are wondering whether AGNC Investment at US$10.86 still offers value or if most of the opportunity is already priced in, this article walks through what the numbers are saying about the stock. The share price has returned 2.0% over the past week and 3.7% over the past month, while year to date the stock is down 0.6%. The 1 year and 3 year returns stand at 39.1% and 85.7% respectively, with a 17.5% return over 5 years. Recent coverage has focused on AGNC Investment's position within...
NasdaqGS:IOSP
NasdaqGS:IOSPChemicals

How Investors Are Reacting To Innospec (IOSP) Dividend Hike And New US$75 Million Buyback

In the past week, Innospec Inc. reported first-quarter 2026 results showing sales of US$453.2 million and net income of US$30.4 million, while also raising its semi-annual dividend by 10% to US$0.92 per share and authorizing a new US$75 million share repurchase program. These moves highlight management’s emphasis on returning cash to shareholders even as operations recover from winter-storm disruptions and segment performance remains mixed. Next, we’ll explore how the higher dividend and...
NasdaqGS:HST
NasdaqGS:HSTHotel and Resort REITs

Host Hotels & Resorts (HST) Valuation Check After Strong Q1 Results Asset Sales And Special Dividend

Host Hotels & Resorts (HST) is in focus after reporting first quarter 2026 results that exceeded profitability expectations, lifted its full year comparable hotel RevPAR guidance, and paired asset sale gains with a special dividend announcement. See our latest analysis for Host Hotels & Resorts. The share price has reacted positively to the first quarter update, with a 1 day share price return of 2.77% and a 7 day share price return of 6.76%. The 1 year total shareholder return of 49.75% and...
NasdaqGM:AVBP
NasdaqGM:AVBPBiotechs

A Look At ArriVent BioPharma (AVBP) Valuation After FDA IND Clearance For ARR-002

ArriVent BioPharma (AVBP) drew fresh attention after announcing FDA clearance of its investigational new drug application for ARR-002, a first-in-class dual-target antibody-drug conjugate for ovarian and endometrial cancers. See our latest analysis for ArriVent BioPharma. Despite a recent dip, with a 1 day share price return down 2.60% and 7 day share price return down 7.20%, ArriVent’s 30 day and year to date share price returns of 14.53% and 38.70%, alongside a 1 year total shareholder...
NYSE:TDAY
NYSE:TDAYMedia

Assessing USA TODAY (TDAY) Valuation After Return To Profitability And Reaffirmed 2026 Earnings Guidance

USA TODAY (TDAY) stock is in focus after the company returned to profitability in the first quarter of 2026, posting positive net income and reaffirming full year earnings guidance despite lower revenue. See our latest analysis for USA TODAY. The earnings return to profit and reaffirmed 2026 guidance have arrived alongside strong momentum, with a 90 day share price return of 26.96% and a 1 year total shareholder return of 105.66%, suggesting sentiment has strengthened around the earnings...
NasdaqGS:RMBS
NasdaqGS:RMBSSemiconductor

Is Rambus (RMBS) Quietly Repositioning Its IP Portfolio Around Next-Gen AI Interconnect Demand?

Rambus recently launched its PCIe 7.0 Switch IP with Time Division Multiplexing, expanding its interconnect portfolio to support bandwidth-intensive AI, cloud, and high-performance computing systems while aiming to improve link utilization and reduce system complexity for large-scale distributed architectures. This new switch IP strengthens Rambus’ position in high-speed interface IP by targeting emerging disaggregated and pooled compute designs that require deterministic, low-latency data...
NasdaqGS:SONO
NasdaqGS:SONOConsumer Durables

Is It Too Late To Consider Sonos (SONO) After Its 44% One Year Rally?

If you are wondering whether Sonos stock still offers value after a strong run or a rough patch, this article breaks down what the current price might be telling you. Over the past year, the stock has returned 44.4%, compared with a 16.1% gain over the last 30 days, while year to date it is down 13.9% and the 5-year return sits at a 55.5% loss. Recent headlines around Sonos have focused on its role in the consumer audio market and how sentiment has shifted around the stock. These stories...
NYSE:ESNT
NYSE:ESNTDiversified Financial

A Look At Essent Group’s Valuation As Q1 Earnings Beat And Dividend Plans Draw Investor Interest

What Essent Group’s latest quarter means for investors Essent Group (ESNT) just posted first quarter results that topped analyst earnings and revenue expectations, alongside an affirmed US$0.35 quarterly dividend and updates on its growing property & casualty reinsurance platform. See our latest analysis for Essent Group. The earnings beat and reaffirmed dividend have arrived alongside a recent pick up in momentum, with a 1 day share price return of 2.52% and 7 day share price return of...
NasdaqGS:CAI
NasdaqGS:CAIBiotechs

Stronger Q1 Results And New AI Oncology Tests Could Be A Game Changer For Caris Life Sciences (CAI)

In early May 2026, Caris Life Sciences reported first-quarter revenue of US$216.17 million versus US$120.92 million a year earlier, with net loss improving to US$0.51 million, while also securing MolDX approval for its Caris ChromoSeq whole genome assay and launching the AI-driven Caris MI Clarity breast cancer prognostic test. Together, these developments highlight Caris’ efforts to broaden its precision oncology portfolio across hematologic malignancies and early-stage breast cancer, while...
NYSE:VLO
NYSE:VLOOil and Gas

Assessing Valero Energy’s Valuation After Profit Turnaround Dividend Affirmation And Improved Guidance

Valero Energy (VLO) has just paired a regular quarterly dividend of $1.20 per share with a sharp swing back to profitability in the first quarter, giving investors fresh numbers to reassess the stock. See our latest analysis for Valero Energy. The recent quarterly profit and steady dividend come against a share price of $236.35, with a 90 day share price return of 16.61% and a year to date share price return of 42.97%. The 1 year total shareholder return of 99.87% suggests strong momentum has...
NasdaqGS:MDLZ
NasdaqGS:MDLZFood

How Investors May Respond To Mondelez International (MDLZ) Stronger Q1 Earnings And Inclusion-Focused Workforce Strategy

Mondelez International recently reported first-quarter 2026 results, with sales rising to US$10.08 billion and net income increasing to US$560 million, alongside higher basic and diluted earnings per share of US$0.44 from continuing operations. In addition, the company’s chief global inclusion and learning officer is scheduled to speak at the ISG Future Workplace Summit in New York, highlighting how its focus on workforce development and inclusion sits alongside its improving financial...
NYSE:NUVB
NYSE:NUVBPharmaceuticals

A Look At Nuvation Bio (NUVB) Valuation After Profit Shift And Taletrectinib FDA And Guideline Milestones

Nuvation Bio (NUVB) has drawn fresh attention after reporting first quarter revenue of US$83.23 million and a profit of US$5.4 million, alongside new FDA and guideline milestones for its oncology drug IBTROZI. See our latest analysis for Nuvation Bio. The stock has been volatile, with a 1-day share price return of a 4.56% decline following a strong 7-day share price return of 8.09%. The year-to-date share price return of a 43.94% decline contrasts with a very large 1-year total shareholder...
NYSE:SLG
NYSE:SLGOffice REITs

A Look At SL Green Realty (SLG) Valuation As One Madison Avenue Wins Award And Reaches Full Leasing

SL Green Realty (SLG) is back in focus after its One Madison Avenue project received the 2026 Urban Land Institute Award for Excellence in Development and reached 100% leasing, alongside flagship peer asset One Vanderbilt. See our latest analysis for SL Green Realty. The award recognition comes as momentum in SL Green Realty’s stock has picked up, with a 6.77% 7 day share price return and a 20.55% 30 day share price return. The 1 year total shareholder return is a 14.13% loss, while the 3...
NYSE:SPXC
NYSE:SPXCMachinery

A Look At SPX Technologies (SPXC) Valuation After Raised 2026 Revenue Guidance And Strong Q1 Results

SPX Technologies (SPXC) drew investor attention after first quarter sales reached US$566.8 million with net income of US$59.9 million, alongside higher full year 2026 revenue guidance in the range of US$2.575 billion to US$2.645 billion. See our latest analysis for SPX Technologies. The latest earnings update and raised 2026 revenue guidance came as the share price has been relatively flat year to date, with a 0.99% share price return. Total shareholder return over the past year is 37.43%,...
NYSE:BWA
NYSE:BWAAuto Components

BorgWarner’s Reaffirmed 2026 Outlook and EV Wins Might Change The Case For Investing In BWA

In early May 2026, BorgWarner reported first‑quarter 2026 sales of US$3,533 million and net income of US$242 million, while maintaining full‑year guidance that targets net sales of US$14.00–US$14.30 billion and a U.S. GAAP operating margin of 9.7%–9.9%. A wave of recent program wins in electrified and emissions-focused technologies, spanning Asian eMotor awards and a Euro 7 commercial vehicle platform, suggests BorgWarner is deepening its role in next‑generation propulsion across both...
NasdaqGM:LNTH
NasdaqGM:LNTHMedical Equipment

Assessing Lantheus Holdings (LNTH) Valuation After Recent Share Price Momentum

Recent performance and business snapshot Lantheus Holdings (LNTH) has drawn attention after a stretch of strong share price performance, with the stock up over the past week, month and past 3 months, while also showing a double digit 1 year total return. The company develops diagnostic and therapeutic products used in the detection and treatment of heart disease, cancer and other conditions, reporting revenue of US$1,546.178 million and net income of US$279.031 million from its portfolio of...
NasdaqGS:ARQT
NasdaqGS:ARQTBiotechs

A Look At Arcutis Biotherapeutics (ARQT) Valuation After Q1 2026 Results And ZORYVE Label Expansion Efforts

Arcutis Biotherapeutics (ARQT) is in focus after reporting Q1 2026 revenue of US$105.4 million, a narrowed net loss of US$11.3 million, positive operating cash flow, and reaffirmed full year revenue guidance. See our latest analysis for Arcutis Biotherapeutics. The stock closed at US$20.66 after the results, with a 1-day share price return of -14.52% and a year to date share price return of -28.76%. However, the 1-year total shareholder return is 52.87%, which suggests recent momentum has...